News

According to Kyowa Kirin, the investigational selective adenosine A 2A receptor antagonist has had its PDUFA action date set for August 27, 2019.

Here’s a brief look at therapies for neurological disorders that the FDA has approved within the past 6 months.

The director of the Jefferson Headache Center at Jefferson University Hospital discusses the problem with traditional nasal sprays and how improvements in formulation and delivery can improve efficacy.

The Professor in UCLA's Department of Neurology and Director of the UCLA MS Program spoke about disease-modifying therapies that would complement anti-inflammatories by targeting neurodegenerative processes.

Patient management 90 days after amyloid PET changed in 60.2% of patients with MCI and 63.5% of patients with dementia of uncertain etiology.

A young man sustained a serious head injury in a car accident, but routine brain CT and MRI scans are normal. Your next step?

The Senior Vice President for Research and Training at Kessler Foundation spoke about research he and colleagues have developed at the Kessler Foundation to aid with cognitive problems in persons with MS.

The administration is seeking help from the medical community and the public to increase risk awareness and report past or future adverse events associated with e-cigarette use.

The professor of neurology at Mayo Clinic spoke about the challenges he faces in diagnosing and treating hereditary ATTR amyloidosis polyneuropathy.

The Professor in UCLA's Department of Neurology and Director of the UCLA MS Program stressed the importance of basing research on clinical observations, understanding them in the lab, then designing novel clincal trials.

Survey respondents expressed willingness to participate in a randomized trial to evaluate the benefit of acute internal carotid stenting in patients undergoing endovascular thrombectomy.

The MEK 1/2 inhibitor was previously granted an orphan drug designation by the FDA in February 2018 and resulted in partial responses in 72% of patients in the phase 2 SPRINT trial.

Despite known teratogenicity risks, many women of childbearing age with epilepsy are prescribed valproate, topiramate, and phenytoin.

The neurologist at Cleveland Clinic Mellen MS Center spoke about the issues in multiple sclerosis that need to be addressed.

Your patient is a former linebacker with recently diagnosed amyotrophic lateral sclerosis, who asks if football injuries caused his disease. What will you tell him?

The professor of neurology at Harvard Medical School discussed differentiating pediatric MS from other CNS disorders, as well as the process of treating and managing these patients.

The Senior Vice President for Research and Training at Kessler Foundation discussed the results of the SUNBEAM trial, which indicated that ozanimod resulted in sustained improvement in cognitive processing speed, supporting its efficacy in relapsing MS.

Experts say that while CBD and THC may have potential in multiple sclerosis and epilepsy, research on the endocannabinoid system is in its infancy—and the literature isn’t perfect.

Neurology News Network for the week of March 30, 2019.

The EMD Serono product was approved based on data which displayed a significant decrease in the number of relapses experienced by patients with MS who had ≥1 relapse in the previous year, compared to placebo.

The study author, a pediatric neurologist at Baylor College of Medicine and director of the Blue Bird Circle Rett Center at Texas Children’s Hospital, spoke about the investigational Rett syndrome treatment’s potential going forward.